John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies in the perioperative setting, diagnosis with consideration for hereditary alpha tryptasemia, and the optimal timing for the addition of avapritinib to the chosen therapies.
In an interview conducted at the 2024 Congress of the European Hematology Association in Madrid, Spain, Lindsay Rein, MD, Duke University Medical Center, Durham, North Carolina, provided insights…
Surgeon Commander VA Arun, INHS Asvini, Colaba, Mumbai, and Anil Handoo, MD, BLK-Max Superspeciality Hospital, Delhi, discuss systemic mastocytosis. They review classification and diagnostic criteria and the clinical…
Systemic mastocytosis, a rare blood disorder, affects the entire body. There are many challenges associated with living with this systemic mastocytosis that are centered around reducing the frequency…
In an interview conducted at the 2024 American Society of Hematology Annual Meeting in San Diego, California, Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center,…
